Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year.
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will be determined. * Trial with medicinal product
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Chemopreventive application (Acitretin)
Clinic for Dermatology University Hospital of Zurich
Zurich, Switzerland
Plasma levels acitretin
Time frame: 2009
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.